The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung trial explores metastasis-associated alterations and potential prognostic markers.
 
Abderaouf Hamza
No Relationships to Disclose
 
Pierre Gestraud
No Relationships to Disclose
 
Maryam Karimi
No Relationships to Disclose
 
Alicia Tran-Dien
No Relationships to Disclose
 
Sophie Vacher
No Relationships to Disclose
 
Quentin Peretti
No Relationships to Disclose
 
Ludovic Lacroix
No Relationships to Disclose
 
Isabelle Soubeyran
Research Funding - AstraZeneca (Inst)
 
Pascal Jezequel
No Relationships to Disclose
 
Samia Melaabi
No Relationships to Disclose
 
Trenton Dailey-Chwalibóg
No Relationships to Disclose
 
Marta Jimenez
No Relationships to Disclose
 
Stefan Michiels
Consulting or Advisory Role - Biophytis; IQvia; Kedrion Biopharma; Roche; SERVIER; Yuhan
 
Nicolas Servant
No Relationships to Disclose
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche
 
Fabrice Andre
Consulting or Advisory Role - AstraZeneca (Inst); Boston Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Lilly; Lilly (Inst); N-Power Medicine (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); ROCHE (Inst); SERVIER (Inst)
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Guardant Health (Inst); Lilly (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Sanofi/Aventis (Inst); SERVIER (Inst)
Consulting or Advisory Role - Abbvie (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Enliven Therapeutics (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Takeda (Inst)
 
Maud Kamal
No Relationships to Disclose
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Ivan Bieche
No Relationships to Disclose